GlassScriptPhysician profile
Brian C Boulmay
NPI 1164505285
$740.66
in general payments reported to CMS, 2019-2025
19 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $19.38 · 2021: $11.92 · 2022: $47.90 · 2023: $101 · 2024: $48.37 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $135.66 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $100.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.19 | 2019-2023 | |
| Amgen INC. | $55.60 | 2019 | |
| Janssen Biotech, INC. | $47.90 | 2022 | |
| Lilly USA, LLC | $41.55 | 2019-2023 | Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $34.99 | 2019 | |
| Astellas Pharma US INC | $33.28 | 2019-2020 | |
| Celgene Corporation | $32.81 | 2023-2024 | Reblozyl |
| Pfizer INC. | $32.46 | 2024 | |
| Genentech USA, INC. | $30.24 | 2019 | |
| Gilead Sciences, INC. | $24.64 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $23.37 | 2025 | Sylvant |
| E.R. Squibb & Sons, L.L.C. | $18.39 | 2019 | |
| Array Biopharma INC | $16.43 | 2025 | Xalkori, Lorbrena, Braftovi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $15.76 | 2025 | Monoferric |
| Exelixis INC. | $14.14 | 2019 | |
| Eisai INC. | $13.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Boulmay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.